Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.69
- Piotroski Score 3.00
- Grade Buy
- Symbol (EQ)
- Company Equillium, Inc.
- Price $0.70
- Changes Percentage (-1.39%)
- Change -$0.01
- Day Low $0.68
- Day High $0.77
- Year High $3.25
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.35
- Trailing P/E Ratio -2.29
- Forward P/E Ratio -2.29
- P/E Growth -2.29
- Net Income $-13,335,000
Income Statement
Quarterly
Annual
Latest News of EQ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TV tonight: Emily Watson stars in the blockbuster Dune prequel
"Dune: Prophecy" focuses on a religious order 10,000 years before Timothée Chalamet's era. Plus, "Panorama" explores technology combating climate change....
By The Guardian | 1 day ago -
Alta Equipment Group Inc. (ALTG): A Bull Case Theory
Alta Equipment Group Inc. (ALTG) is a prominent heavy-equipment distributor in North America, known for strategic partnerships and aggressive acquisition strategy....
By Yahoo! Finance | 1 day ago -
A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity
ROE is a key metric to assess a company's ability to generate returns on shareholder investments. Zynex Inc. has an ROE of 13%, indicating its success in turning equity into profits. However, its high...
By Yahoo! Finance | 1 day ago
